Ocular Therapeutix, Inc. (OCUL)
6.96
-0.33
(-4.53%)
USD |
NASDAQ |
Oct 02, 16:00
6.98
+0.02
(+0.29%)
After-Hours: 20:00
Ocular Therapeutix Enterprise Value : 1.009B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.009B |
| October 01, 2026 | 1.082B |
| September 30, 2026 | 1.165B |
| September 29, 2026 | 1.209B |
| September 28, 2026 | 1.162B |
| September 25, 2026 | 1.600B |
| September 24, 2026 | 1.637B |
| September 23, 2026 | 1.677B |
| September 22, 2026 | 1.786B |
| September 21, 2026 | 1.674B |
| September 18, 2026 | 1.674B |
| September 17, 2026 | 1.707B |
| September 16, 2026 | 1.648B |
| September 15, 2026 | 1.718B |
| September 14, 2026 | 1.835B |
| September 11, 2026 | 1.784B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.999B |
| September 08, 2026 | 1.977B |
| September 04, 2026 | 1.817B |
| September 03, 2026 | 1.817B |
| September 02, 2026 | 1.874B |
| September 01, 2026 | 1.802B |
| August 31, 2026 | 1.784B |
| August 28, 2026 | 1.756B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.857B |
| August 26, 2026 | 1.846B |
| August 25, 2026 | 1.870B |
| August 24, 2026 | 1.848B |
| August 21, 2026 | 1.914B |
| August 20, 2026 | 1.916B |
| August 19, 2026 | 2.057B |
| August 18, 2026 | 1.898B |
| August 17, 2026 | 1.819B |
| August 14, 2026 | 1.685B |
| August 13, 2026 | 1.699B |
| August 12, 2026 | 1.727B |
| August 11, 2026 | 1.624B |
| August 10, 2026 | 1.510B |
| August 07, 2026 | 1.499B |
| August 06, 2026 | 1.400B |
| August 05, 2026 | 1.347B |
| August 04, 2026 | 1.367B |
| August 03, 2026 | 1.325B |
| July 31, 2026 | 1.275B |
| July 30, 2026 | 1.341B |
| July 29, 2026 | 1.317B |
| July 28, 2026 | 1.336B |
| July 27, 2026 | 1.378B |
| July 24, 2026 | 1.348B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | 118.09M |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Theravance Biopharma, Inc. | 567.41M |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.76M |
| Revenue (Quarterly) | 13.48M |
| Total Expenses (Quarterly) | 92.24M |
| EPS Diluted (Quarterly) | -0.3501 |
| Gross Profit Margin (Quarterly) | 85.08% |
| Profit Margin (Quarterly) | -584.5% |
| Earnings Yield | -20.30% |
| Normalized Earnings Yield | -20.35 |